LI

LODH Immunology Fund

Europe, Geneve, Switzerland, Geneva

Description

The LODH Immunology Fund is a Swiss open-ended mutual fund managed by Lombard Odier Darier Hentsch & Cie, a Swiss private bank.

Investor Profile

LODH Immunology Fund has backed more than 6 startups, with 0 new investments in the last 12 months alone. The firm has led 1 rounds, about 17% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series A, Series Unknown, Series B rounds (top funding stages).
  • Majority of deals are located in Switzerland, Denmark.
  • Strong thematic focus on Biotechnology, Medical, Health Care.

Stage Focus

  • Series A (50%)
  • Series Unknown (33%)
  • Series B (17%)

Country Focus

  • Switzerland (67%)
  • Denmark (33%)

Industry Focus

  • Biotechnology
  • Medical
  • Health Care
  • Pharmaceutical
  • Therapeutics
  • Manufacturing
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does LODH Immunology Fund frequently co-invest with?

IF
Europe, Basel-Landschaft, Switzerland, Bubendorf
Co-Investments: 1
InnoVentures Capital Partners
North America, Utah, United States, Salt Lake City
Co-Investments: 1
Novartis Venture Fund
Europe, Basel-Stadt, Switzerland, Basel
Co-Investments: 4
Apax Partners Development
Europe, Ile-de-France, France, Paris
Co-Investments: 1
Aravis Ventures
Europe, Zurich, Switzerland, Zürich
Co-Investments: 2
BB
Europe, Solothurn, Switzerland, Wiler
Co-Investments: 2
Index Ventures
North America, California, United States, San Francisco
Co-Investments: 2
Co-Investments: 1
Pictet Private Equity Investors S.A.
Europe, Geneve, Switzerland, Geneva
Co-Investments: 2

What are some of recent deals done by LODH Immunology Fund?

NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series UnknownMay 12, 2009
Amount Raised: $54,800,000
NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series BJun 1, 2006
Amount Raised: $46,000,000
ESBATech

Schlieren, Zurich, Switzerland

ESBATech develops fully human antibody fragments for therapeutic applications, applying the single-chain antibody framework.

BiotechnologyHealth CareTherapeutics
Series AMay 14, 2002
Amount Raised: $8,996,617
7TM Pharma

Lyngby, Hovedstaden, Denmark

7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, asthma, and more.

BiotechnologyHealth CareTherapeutics
Series ASep 27, 2001
Amount Raised: $15,000,000
Genmab

Copenhagen, Hovedstaden, Denmark

Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.

BiotechnologyHealth CareManufacturingMedical
Series UnknownJun 13, 2000
Amount Raised: $40,500,000
NovImmune

Plan-les-ouates, Geneve, Switzerland

NovImmmune develops therapeutic monoclonal antibodies to treat patients suffering from immune-related disorders.

BiotechnologyMedicalPharmaceutical
Series AMay 1, 2000
Amount Raised: $14,000,000

Find More Investors Like LODH Immunology Fund

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

LODH Immunology Fund | Pipeseed